The District Hospital Santarém to Adopt Biolog Transfusion Solution to Improve Red Blood Cells Traceability
29.3.2021 14:57:00 EEST | Business Wire | Press release
The District Hospital of Santarém, a well-recognized healthcare center located in the central region of Portugal, has chosen Biolog Transfusion Solution to optimize its blood components’ management between its healthcare services and blood transfusion department. In operation since November 2020, this solution provides real-time traceability to red blood cells, from reception to release for transfusion.
Based on RFID, Biolog Transfusion Solution connects healthcare professionals to essential product information. By offering real-time precise physical location for each blood product unit, this cutting-edge technology helps to better drive inventory management and enhance patients’ blood product reservations. Besides, this traceability allows unused red blood cell bags to be more reliably returned to the Blood Bank for potential new patient assignation before the expiration date. Combining the technology with 24/7 accurate digital information contributes to better utilization of available products and in reducing wastage, a key requirement when we know that about 5% of these vital resources can be unavailable for medical usage1.
“The implementation of the Biolog Transfusion Solution proved to be a good tool to improve the traceability of the transfusion process and, consequently, the quality of the service provided by the blood transfusion department. By tracking red blood bags, it’s possible to obtain information on all procedures performed with them, from reception at the department to transfusion at the inpatient service”, said Dra Rute Ribeiro, technical coordinator and responsible for quality of Santarém District Hospital Blood Bank.
“We have worked alongside the District Hospital of Santarém to define the right tools for facing their challenges, and we are pleased to see that Biolog Transfusion Solution meets their needs. At biolog-id we are committed to developing state of the art solutions to ensure the availability and the quality of blood products which will ultimately serve patients”, declares Philippe Jacquet, Executive Director of Sales EMEA/LATAM at biolog-id.
“The real time capacity to locate blood components, as well as monitoring transfusion processes is the main achievement made possible by using RFID technology. That is really a forwarding security step!”, explains Dr. João Moura, Director of Santarém District Hospital Blood Bank.
By combining software, equipment, and tags, the modular end-to-end Biolog Transfusion Solution offers traceability of blood components products at every stage of the process. Biolog-id’s flexible approach allows customization of the solution to meet any infrastructure constraints, from blood centers, blood banks, and hospitals.
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds.
Company URL: www.biolog-id.com
About District Hospital of Santarém:
The District Hospital of Santarém (HDS) is a Corporate Public Entity located in the city of Santarém in the central region of Portugal, in full operation since 1985. The Hospital is part of the Portuguese National Health Service (SNS).
The Hospital was projected in the late 70's with more than 500 beds and the objective of offering a new health infrastructure for the city. The Hospital is equipped with all the main medical and surgical specialties, serving a population of approximately 200,000 inhabitants. It has now a total of 419 beds, where more than 6,000 blood transfusions are delivered each year.
Website URL: https://www.hds.min-saude.pt/
About Xerys Gestion:
Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies. As such, Xerys Gestion supports companies in industries undergoing major transformation to address economic, environmental and societal challenges that have great ambitions for their growth and international expansion. In its market, Xerys Gestion stands out as much for its modus operandi and the strategic and operational support it provides to portfolio companies, as for the range of à la carte investment opportunities offered to investors and the firm’s close relations with them, or its sector-based approach. Lastly, Xerys Gestion has considerable sector expertise, bolstered by a strategic committee made up of recognized specialists and experts in key sectors. Xerys Gestion manages 200 million euros in assets, with a portfolio of nine companies.
For more information visit www.xerys.com or find us on LinkedIn @Xerys.
1 Source: World Health Organization
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005415/en/
Contact information
Contact: Astrid Billard, astrid.billard@biolog-id.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 23:08:00 EEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 22:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, security, and performance required for enterprise environments. These capabilities enable organizations to move from pilot to production with confiden
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recollection, and real-time business data. Lack of governance, auditability, and operational control drives up compute costs while diminishing productivity and revenue. “2026 is the year organizations move from AI experimentation to a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
